Sequential versus alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Mateos MV et al. Blood. 2015 Oct 23. pii: blood-2015-08-666537. [Epub ahead of print].

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
Cavo M et al. Leukemia. 2015 Oct 7. doi: 10.1038/leu.2015.274. [Epub ahead of print].

Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant.
Jimenez-Zepeda VH et al. Leuk Lymphoma. 2015 Oct 8:1-4. [Epub ahead of print]

Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
Hartmann T et al. Cochrane Database Syst Rev. 2015 Oct 20;10:CD010615. [Epub ahead of print].

A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.
Silvennoinen R et al. Bone Marrow Transplant. 2015 Oct 5. doi: 10.1038/bmt.2015.236. [Epub ahead of print].

Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: Granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF.
Jang JE et al. Leuk Lymphoma. 2015 Oct 1:1-29. [Epub ahead of print].

Hematopoietic progenitor cell mobilization with “just-in-time” plerixafor approach is a cost-effective alternative to routine plerixafor use.
Veltri L et al. Cytotherapy. 2015 Oct 13. pii: S1465-3249(15)01058-0. doi: 10.1016/j.jcyt.2015.09.002. [Epub ahead of print].

Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Kikuchi T et al. Int J Hematol. 2015 Oct 6. [Epub ahead of print].

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma.
Vu T et al. Blood Cancer J. 2015 Oct 23;5:e363. doi: 10.1038/bcj.2015.91.